DE69634563D1 - Verbesserte verfahren zur transfektion der t-zellen - Google Patents

Verbesserte verfahren zur transfektion der t-zellen

Info

Publication number
DE69634563D1
DE69634563D1 DE69634563T DE69634563T DE69634563D1 DE 69634563 D1 DE69634563 D1 DE 69634563D1 DE 69634563 T DE69634563 T DE 69634563T DE 69634563 T DE69634563 T DE 69634563T DE 69634563 D1 DE69634563 D1 DE 69634563D1
Authority
DE
Germany
Prior art keywords
cells
transfection
improved methods
gene
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69634563T
Other languages
English (en)
Other versions
DE69634563T2 (de
Inventor
H June
B Thompson
Suil Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan
US Department of Navy
Original Assignee
University of Michigan
US Department of Navy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/475,136 external-priority patent/US6692964B1/en
Application filed by University of Michigan, US Department of Navy filed Critical University of Michigan
Application granted granted Critical
Publication of DE69634563D1 publication Critical patent/DE69634563D1/de
Publication of DE69634563T2 publication Critical patent/DE69634563T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69634563T 1995-05-04 1996-05-02 Verbesserte verfahren zur transfektion der t-zellen Expired - Lifetime DE69634563T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US43509595A 1995-05-04 1995-05-04
US435095 1995-05-04
US475136 1995-06-07
US08/475,136 US6692964B1 (en) 1995-05-04 1995-06-07 Methods for transfecting T cells
PCT/US1996/006200 WO1996034970A1 (en) 1995-05-04 1996-05-02 Improved methods for transfecting t cells

Publications (2)

Publication Number Publication Date
DE69634563D1 true DE69634563D1 (de) 2005-05-12
DE69634563T2 DE69634563T2 (de) 2006-02-16

Family

ID=27030423

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69634563T Expired - Lifetime DE69634563T2 (de) 1995-05-04 1996-05-02 Verbesserte verfahren zur transfektion der t-zellen

Country Status (7)

Country Link
US (1) US20060246587A1 (de)
EP (1) EP0824594B1 (de)
JP (3) JP4031033B2 (de)
AT (1) ATE292689T1 (de)
CA (1) CA2220226C (de)
DE (1) DE69634563T2 (de)
WO (1) WO1996034970A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9907366D0 (en) * 1999-03-30 1999-05-26 Medical Res Council Method for expressing proteins
KR100715926B1 (ko) * 2000-08-16 2007-05-08 다카라 바이오 가부시키가이샤 항원 특이적 세포 상해성 ｔ 세포 확대 배양 방법
US6627442B1 (en) * 2000-08-31 2003-09-30 Virxsys Corporation Methods for stable transduction of cells with hiv-derived viral vectors
DE60232083D1 (de) 2001-08-15 2009-06-04 Takara Bio Inc Expansionskulturverfahren für antigenspezifische zytotoxische t-lymphozyten
US8728811B2 (en) * 2002-03-25 2014-05-20 Takara Bio Inc. Process for producing cytotoxic lymphocyte
EP1666589B1 (de) 2003-08-22 2010-02-17 Takara Bio Inc. Verfahren zur herstellung zytotoxischer lymphozyten
WO2005030251A1 (en) * 2003-09-22 2005-04-07 Xcyte Therapies, Inc. Compositions and methods to accelerate hematologic recovery
JPWO2006101205A1 (ja) * 2005-03-25 2008-09-04 株式会社カネカ Ｔ細胞の活性化方法及び活性化ｔ細胞製造用キット
JP4929174B2 (ja) 2005-08-17 2012-05-09 タカラバイオ株式会社 リンパ球の製造方法
EA016168B1 (ru) * 2005-09-30 2012-02-28 Такара Био Инк. Способ получения т-клеточной популяции и ее применение
WO2016007827A1 (en) * 2014-07-11 2016-01-14 Anthrogenesis Corporation Methods of improving vector transduction efficiency into t lymphocytes
KR20170135966A (ko) * 2015-04-13 2017-12-08 맥스시티 인코포레이티드 게놈 dna를 변형시키기 위한 방법 및 조성물
US10294454B2 (en) 2016-08-24 2019-05-21 General Electric Company Methods and kits for cell activation

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7873187A (en) * 1986-08-08 1988-02-24 University Of Minnesota Method of culturing leukocytes
US5858358A (en) * 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
IL92382A (en) * 1988-11-23 1994-12-29 Univ Michigan Use of a ligand specific for CD28 in the manufacture of medicament
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5272082A (en) * 1992-03-30 1993-12-21 The Wistar Institute Of Anatomy & Biology Cytotoxic T-ALL cell lines and uses therefor
AU5729294A (en) * 1992-11-25 1994-06-22 Tanox Biosystems, Inc. Conjugates and constructs including anti-cd28 and anti-cd3 binding molecules
JPH08509606A (ja) * 1993-04-20 1996-10-15 ロビンソン，ウィリアム エス． 細胞内感染因子に感染した個体を処置する方法および物質
DE69434342T2 (de) * 1993-06-04 2006-03-16 The United States Of America Represented By The Secretary Of The Navy Verfahren zur selektiven Stimulierung der T-Zellproliferation.
FR2707091B1 (fr) * 1993-06-30 1997-04-04 Cohen Haguenauer Odile Vecteur rétroviral pour le transfert et l'expression de gènes dans des cellules eucaryotes.
AU7405294A (en) * 1993-07-26 1995-02-20 Dana-Farber Cancer Institute B7-2: ctl a4/cd 28 counter receptor
US5733543A (en) * 1994-04-29 1998-03-31 Nabel; Gary J. Introduction of HIV-protective genes into cells by particle-mediated gene transfer
CA2191586A1 (en) * 1994-06-03 1995-12-14 Carl H. June Methods for selectively stimulating proliferation of t cells
AU2701895A (en) * 1994-06-07 1996-01-05 Regents Of The University Of Minnesota Methods for inhibiting antigen specific t cell responses
US6576236B1 (en) * 1994-07-01 2003-06-10 Dana Farber Cancer Institute Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
US5795790A (en) * 1994-07-20 1998-08-18 Cytotherapeutics, Inc. Method for controlling proliferation and differentiation of cells encapsulated within bioartificial organs
EP0782627A1 (de) * 1994-08-31 1997-07-09 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. Genetisch veränderte t-zellen
US5827642A (en) * 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US6692964B1 (en) * 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) * 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells

Also Published As

Publication number Publication date
CA2220226A1 (en) 1996-11-07
JPH11505419A (ja) 1999-05-21
JP2006109844A (ja) 2006-04-27
EP0824594A1 (de) 1998-02-25
CA2220226C (en) 2008-10-21
WO1996034970A1 (en) 1996-11-07
ATE292689T1 (de) 2005-04-15
US20060246587A1 (en) 2006-11-02
DE69634563T2 (de) 2006-02-16
JP4189007B2 (ja) 2008-12-03
JP2007125041A (ja) 2007-05-24
JP4031033B2 (ja) 2008-01-09
EP0824594B1 (de) 2005-04-06

Similar Documents

Publication Publication Date Title
EP1586655A3 (de) Verbesserte Methoden zur Transfektion von T Zellen
DE69634563D1 (de) Verbesserte verfahren zur transfektion der t-zellen
DE69736598D1 (de) Ribonukleaseresistente rna präparation und seine verwendung
ATE224457T1 (de) Verfahren zur identifizierung von nukleinsäuren, welche agenzien kodieren, die zelluläre phenotypen beeinflussen
DE3854125T3 (de) VERBESSERTES VERFAHREN ZUR HERSTELLUNG VON FAKTOR VIII:c-TYP-PROTEINEN.
ATE279912T1 (de) Verfahren zur zelltransfektion mit liposomal- verkapselten nukleinsäuren
ATE298253T1 (de) In vivo gentransfermethoden zur wundheilung
DE69837041D1 (de) Verfahren und mikroorganism zur herstellung von purin-nukleosiden durch fermentation
ES2059478T3 (es) Co-expresion en celulas eucarioticas.
ATE391175T1 (de) Multidrug resistenz gen
HUP0001937A2 (hu) Új vegyületek, eljárás előállításukra és alkalmazásuk nukleinsavak sejtekbe való bevitelére
ATE278024T1 (de) Methode zur herstellung von rekombinanten zellen
AU8110487A (en) DNA molecules coding for proteins targeted to plant cell walls
DE69723855D1 (de) Verfahren zur herstellung von polypeptiden in surfaktinmutanten von bacillus zellen
ATE44047T1 (de) Verfahren zur herstellung von interferonen.
DE69535865D1 (de) Transferase und Amylase, Verfahren zur Herstellung dieser Enzyme, ihre Verwendung und kodierende Gene
ATE524198T1 (de) Verfahren zur einführung von genen in säugetiere
ATE338814T1 (de) Verfahren zur kultivierung von zellen und zur vermehrung von viren
DE3687948D1 (de) Verfahren und nukleinsaeure zur herstellung von lecithin: cholestrinacyltransferase.
DE69634297D1 (de) Verfahren zur verlängerung der expression eines interessierenden gens unter verwendung von löslichen ctla4 molekülen
DE3579733D1 (de) Verfahren zur trennung von tierischen zellen aus fluessiger kultur.
DE60040864D1 (de) Verfahren zur selektiven isolierung einer nukleinsäure
DK0706567T3 (da) Peptidfamilie betegnet xenoxiner
PT801682E (pt) Processo para a producao de proteinas
DE69823813D1 (de) Malignitätsunterdrückung durch verwendung von ribonucleotid reductase r1

Legal Events

Date Code Title Description
8364 No opposition during term of opposition